Please use this identifier to cite or link to this item: http://repo.tma.uz/xmlui/handle/1/876
Title: IMPACT OF THE NEW DRUG REOMANNISOL IN THE TREATMENT OF EXPERIMENTAL DIABETIC FOOT SYNDROME
Authors: Ernazarov Khojimurod Irsalievich., Sadullaeva Klara Khamidullaevna
Keywords: experimental model of diabetic foot, experimental animals, diabetes mellitus, alloxan, surgical debridement, rheomannisol.
Issue Date: 2024
Publisher: O'zbekiston, Toshkent
Series/Report no.: UDC;616-001.36-02:616.379-008.64-092
Abstract: The aim of the study was to compare the effect of the new drug “Rheomannisol” on physiological parameters in the treatment of experimental diabetic foot syndrome. Material and methods. An experimental study was carried out on 140 outbred male rats weighing 220-250 g, kept in the TMA vivarium. The experimental animals were divided into 4 groups: the 1st group was intact; 2nd group – the creation of an experimental model of alloxan diabetes mellitus; 3rd control group - against the background of alloxan diabetes, the creation of an experimental model of a diabetic foot using traditional complex treatment; 4th experimental group - on an experimental model of diabetic foot - traditional treatment and reomannisol. On the skin of each rat’s right hind paw’s footpad, a full-thickness rectangular wound measuring 2 mm×5 mm was created with a scalpel. Every day, the wounds were treated with the traditional method of treatment (5% alcohol solution of iodine and levomekol ointment) until the end of the experiment, for the experimental group, the local traditional method of treatment and intraperitoneal administration of the new Reomannisol preparation were used 1 time per day at a dose of 1 ml of Reomannisol per 100 g of animal body weight for 5 days. Results. The total integral severity assessment index calculated by us, reflecting the state of immunocompetence, indicates the degree of compensation or decompensation of the natural immune system of experimental animals. Detoxification therapy with Rheosorbilact, and especially Rheomannisol, reduces the effects of intoxication, increases the body's compensatory capabilities and an earlier transition to a compensated and satisfactory state. Conclusion: The results obtained indicate that the new domestic drug Rheomannisol is not inferior to the classic Rheosorbilact, has antioxidant properties, has a detoxifying effect of “biochemical sanitation” and restores the physiological functions of cells, which makes it possible to recommend for use in the treatment of diabetic foot syndrome.
URI: http://repo.tma.uz/xmlui/handle/1/876
Appears in Collections:Articles

Files in This Item:
File Description SizeFormat 
Statya 4.pdfIMPACT OF THE NEW DRUG REOMANNISOL IN THE TREATMENT OF EXPERIMENTAL DIABETIC FOOT SYNDROME687.09 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.